Design, Synthesis, Anticancer Properties, and Molecular Dynamics of New Quinazolinonethioacetohydrazide‐1,2,3‐Triazoles
Chemistry & Biodiversity · 2025
DOI: 10.1002/cbdv.202501526 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2025. Verfasst von Aida Iraji und 4 weiteren Autor:innen. Beteiligte Einrichtung: Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: Antineoplastic Agents, Drug Design, Molecular Dynamics Simulation, Quinazolinones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Tehran University of Medical Sciences.
Abstract (Originalsprache)
A novel series of quinazolinonethioacetohydrazide‐1,2,3‐triazole hybrids 13a–l was synthesized via a multi‐step process starting from isatoic anhydride, followed by the condensation reaction with carbon disulfide (CS 2 ), hydrazide formation, and the conduction of click chemistry reaction. Different spectroscopic techniques structurally characterized the synthesized compounds. The anticancer activity of the compounds was evaluated against MCF‐7 (breast) and SW480 (colon) cancer cell lines, while HEK 293 (normal cells) was used as a noncancerous control. Compound 13c exhibited the most potent and selective cytotoxicity, particularly against SW480 (IC 50 = 29.83 µM) and MCF‐7 (IC 50 = 17.32 µM) cancer cell lines, while demonstrating negligible toxicity toward normal HEK 293 cells. Cell cycle analysis indicated that 13c induced G2/M phase arrest and promoted apoptosis in MCF‐7 cells, as confirmed by annexin V/PI staining. In silico docking studies revealed strong binding of 13c to the vascular endothelial growth factor (VEGF) receptor, with key hydrogen bonding and π–π interactions at critical active‐site residues. In addition, 100 ns molecular dynamics simulations validated the stability of the VEGF– 13c complex and the persistence of binding interactions, supporting its role as a strong and stable VEGFR inhibitor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
- Central Research Laboratory, Shiraz University of Medical Sciences, Shiraz, Iran.
- Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
- Medicinal Plants Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
- Persian Medicine and Pharmacy Research Center, Tehran University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Mina Saeedi
Förderung
- Tehran University of Medical Sciences
Zitieren
APA
Iraji, A., Irajie, C., Nasouhi, F., Saeedi, M., & Akbarzadeh, T. (2025). Design, Synthesis, Anticancer Properties, and Molecular Dynamics of New Quinazolinonethioacetohydrazide‐1,2,3‐Triazoles. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202501526
Vancouver
Iraji A, Irajie C, Nasouhi F, Saeedi M, Akbarzadeh T. Design, Synthesis, Anticancer Properties, and Molecular Dynamics of New Quinazolinonethioacetohydrazide‐1,2,3‐Triazoles. Chemistry & Biodiversity. 2025. doi:10.1002/cbdv.202501526
BibTeX
@article{Iraji2025,
author = {Iraji, Aida and Irajie, Cambyz and Nasouhi, Farnaz and Saeedi, Mina and Akbarzadeh, Tahmineh},
title = {Design, Synthesis, Anticancer Properties, and Molecular Dynamics of New Quinazolinonethioacetohydrazide‐1,2,3‐Triazoles},
journal = {Chemistry & Biodiversity},
year = {2025},
doi = {10.1002/cbdv.202501526}
}
EUVIMED